How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency

被引:17
作者
Bhatia, Ajay
Kast, Richard E.
机构
[1] Univ Vermont, Dept Psychiat, Burlington, VT 05401 USA
[2] Ohio State Univ, Harding Hosp, Dept Psychiat, Columbus, OH 43210 USA
关键词
asialoglycoprotein receptor; IgA; immunodeficiency; influenza; lymphocyte homing; neuraminidase; oseltamivir; sialic acid; zanamivir;
D O I
10.2478/s11658-006-0055-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuraminidase ( NA) is an enzyme coded for by the genome of influenza critical for its pathogenicity and survival. Three currently accepted roles for this NA in promoting influenza virulence are: 1. NA cleaves newly formed virus particles from the host cell membrane. Without NA, newly formed virus would remain attached to the cell within which it was produced. 2. NA prevents newly released virus particles from aggregating to each other, preventing clumping that would reduce dissemination. 3. NA promotes viral penetration of sialic acid- rich mucin that bathes and protects respiratory epithelium through which the virus must spread and replicate. We outline here previous research evidence of two further, albeit hypothetical, functions of NA that together could cause disruption the mucosa- IgA axis, creating localized partial immunosuppressed state, enhancing both influenza infection itself and secondary bacterial pneumonia: 4. IgA provides primary immunoglobulin defense of mucosal surfaces. The hinge region of IgA is normally sialylated. IgA denuded of sialic acid is recognized, bound, and cleared by hepatic asialoglycoprotein receptor ( ASGPR). Thus, IgA exposed to free NA would be so denuded and have increased hepatic clearance. 5. NA removes sialic acid moieties from mucosa- residing gamma/ delta T cells or IgA producing B cells. Previous work indicates desialylation of these lymphocytes' outer cell membrane results in altered homing, to bone marrow, away from mucosa. Currently marketed NA inhibitors oseltamivir ( Tamiflu) and zanamivir ( Relenza) are FDA approved in USA for influenza prophylaxis and treatment. These NA inhibitors lower incidence of secondary bacterial infection in cases where an influenza infection occurs despite their use. Moreover, they are ameliorative in patients with secondary bacterial infections treated with antibiotics, a benefit that surpasses the treatment of antibiotics alone. We interpret these last two points as indicating our ascription of localized immunosuppression to influenza's NA could be correct and lead to new treatments of infections generally.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 36 条
[21]   Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis [J].
Monto, AS ;
Webster, A ;
Keene, O .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :23-29
[22]   Drug therapy - Neuraminidase inhibitors for influenza [J].
Moscona, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1363-1373
[23]   Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells [J].
Nitschke, L ;
Floyd, H ;
Ferguson, DJP ;
Crocker, PR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (09) :1513-1518
[24]   Influenza virus neuraminidase contributes to secondary bacterial pneumonia [J].
Peltola, VT ;
Murti, KG ;
McCullers, JA .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (02) :249-257
[25]   Respiratory viruses predisposing to bacterial infections: role of neuraminidase [J].
Peltola, VT ;
McCullers, JA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (01) :S87-S96
[26]   MOLECULAR ASPECTS OF IMMUNOGOBULIN-A1 DEGRADATION BY ORAL STREPTOCOCCI [J].
REINHOLDT, J ;
TOMANA, M ;
MORTENSEN, SB ;
KILIAN, M .
INFECTION AND IMMUNITY, 1990, 58 (05) :1186-1194
[27]   Treatment of influenza with neuraminidase inhibitors: virological implications [J].
Roberts, NA .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 2001, 356 (1416) :1895-1897
[28]   The global impact of influenza on morbidity and mortality [J].
Simonsen, L .
VACCINE, 1999, 17 :S3-S10
[29]   The impact of influenza epidemics on hospitalizations [J].
Simonsen, L ;
Fukuda, K ;
Schonberger, LB ;
Cox, NJ .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :831-837
[30]   EXPRESSION OF DISULFIDE-LINKED AND NON-DISULFIDE-LINKED FORMS OF THE T-CELL RECEPTOR-GAMMA-DELTA HETERODIMER IN HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES [J].
SPENCER, J ;
ISAACSON, PG ;
DISS, TC ;
MACDONALD, TT .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (07) :1335-1338